. One pre-dose bone marrow sample and one 32 hour post-dose sample were inadequate and were excluded. White blood cells were isolated using a Ficoll gradient and stained for specific bone marrow lineage markers (CD45, CD71, CD61, CD38, CD11b, CD14). Cells were then treated with Draq5 (DNA staining dye), and cell cycle analysis was completed using flow cytometry. Percent of cells in each phase of the cell cycle (G1 vs. S/G2/M) were calculated for specific lineage populations (also see Table 2 ). *Draq5 analysis may have been confounded in the granulocyte lineage due to an unexpectedly low percent of viable cells in some samples, particularly the 24 hour samples. Data shown are mean ± SD. • G1T28 induced a G1 cell cycle arrest in most lineages assayed at 24 hours, with some populations maintaining the arrest while others were further arrested at 32 hours • Concomitantly, the percentage of cells in the S/G2/M cell cycle phase was decreased • Analysis of total bone marrow demonstrated an approximate 40% arrest at 24 hours, with partial recovery at 32 hours, which is consistent with both the dog total bone marrow data and the simulations from the PK/PD model • Despite robust inhibition of HSPC proliferation, a single dose of G1T28 did not alter peripheral blood cell counts
• G1T28 demonstrated 2-compartment linear PK, with rapid distribution and nearly linear scaling of clearance with weight • The model predicted a dose of 192 mg/m 2 or greater would induce a 40-50% decrease in total bone marrow proliferation with return to baseline at approximately 48 hours (note that the simulation was for total bone marrow which includes CDK4/6-independent cell populations) and bone marrow aspirates were drawn at various time points (predose [n=5] , and 24 [n=3] or 32 [n=4] hours post G1T28 dose). One pre-dose bone marrow sample and one 32 hour post-dose sample were inadequate and were excluded. White blood cells were isolated using a Ficoll gradient and stained for specific bone marrow lineage markers (CD45, CD71, CD61, CD38, CD11b, CD14). Cells were then treated with Draq5 (DNA staining dye), and cell cycle analysis was completed using flow cytometry. Percent of cells in each phase of the cell cycle (G1 vs. S/G2/M) were calculated for specific lineage populations (also see Table 2 ). *Draq5 analysis may have been confounded in the granulocyte lineage due to an unexpectedly low percent of viable cells in some samples, particularly the 24 hour samples. Data shown are mean ± SD. • G1T28 induced a G1 cell cycle arrest in most lineages assayed at 24 hours, with some populations maintaining the arrest while others were further arrested at 32 hours • Concomitantly, the percentage of cells in the S/G2/M cell cycle phase was decreased • Analysis of total bone marrow demonstrated an approximate 40% arrest at 24 hours, with partial recovery at 32 hours, which is consistent with both the dog total bone marrow data and the simulations from the PK/PD model  clinical concerns raised by myelosuppression commonly lead to chemotherapy dose reductions and limit therapeutic doseintensity
• G1T28 (formerly G1T28-1) is a highly potent, selective, and reversible CDK4/6 inhibitor being developed for intravenous (IV) administration to cancer patients to reduce chemotherapyinduced myelosuppression
• G1T28 acts by transiently producing a G1 cell cycle arrest of hematopoietic stem and progenitor cells (HSPCs) in the bone marrow  G1-arrested HSPC are more resistant to the DNA damaging effects of chemotherapy, thereby preserving bone marrow and immune system function • In preclinical animal models, administration of G1T28 prior to myelosuppressive chemotherapy resulted in:
 improved complete blood cell count (CBC) recovery  preservation of immune system and long-term bone marrow function  ability to tolerate more cumulative chemotherapy
• To rationally design a schedule for administering G1T28 prior to chemotherapy, it is critical to precisely understand the magnitude and duration of G1 cell cycle arrest of HSPCs at a given dose level of G1T28 to ensure that:
1. the effect of G1T28 lasts long enough to avoid releasing HSPCs into the S (DNA synthesis) phase of the cell cycle in the presence of high concentrations of chemotherapy, which could potentially exacerbate myelosuppression 2. the effect of G1T28 does not last too long such that prolonged G1 cell cycle arrest of HSPCs could potentially contribute to myelosuppression
The objective of this study was to characterize the magnitude and duration of G1T28-induced G1 cell cycle arrest in human bone marrow HSPCs, in order to rationally design tolerable and active chemotherapy combination regimens with reduced myelosuppression and maximized anti-tumor activity.
METHODS PHARMACOKINETIC/PHARMACODYNAMIC (PK/PD) MODEL DEVELOPMENT
• Preclinical and clinical data were used to evaluate dose response relationships for HSPC G1 cell cycle arrest and to construct a crossspecies, allometrically-scaled PK/PD model (Representative data from dogs are shown in Figure 1) • The multi-compartment model was constructed in two stages (Table 1) 1. PK data were compiled (doses, routes of administration, observed concentrations, etc) and PK parameters were determined. 2. PD data were layered onto the PK data set, various physiological compartments were created and specific assumptions were entered
• The multi-compartment model was built to simulate the effect of G1T28 on hematopoiesis, with cell proliferation originating at the hematopoietic stem cell and continuing through the various stages of differentiation and ultimately culminating in the release of a mature neutrophil into peripheral circulation (Figure 2) • Model assumptions included transit time through the cell cycle, the number of cells in G1 versus S phase for each level of differentiation, and the life span of mature circulating cells • In the first-in-human Phase 1a safety, PK, and PD study of the CDK4/6 inhibitor G1T28, 12 subjects (Cohort 7) were enrolled to confirm the predicted biologically effective dose (BED) of G1T28 (G1T28-1-01; NCT02243150; Abstract #2527)
• PK/PD model simulations and human PK/PD data from the Table 2 .
• HSPC proliferation was measured prior to dosing (n=5), 24 hours after G1T28 dosing (n=3), or 32 hours after G1T28 dosing (n=4)
• Two bone marrow samples (one at pre-dose and one at 32 hour post-dose) were heavily contaminated with peripheral blood, technically inadequate, and removed from the cell cycle analysis datasets 
